What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Growth-hormone-releasing peptide-2 · Pralmorelin
Vialdyne buyer fit
This Vialdyne page is intentionally positioned for compounding-pharmacy, clinic, and regulated procurement teams evaluating GHRP-2. It is not the broad research monograph for this SKU; the page emphasizes buyer qualification, release testing, documentation depth, and whether the active fits the destination-market workflow before pricing.
Overview
GHRP-2, also catalogued as Pralmorelin, is a synthetic hexapeptide secretagogue acting at the ghrelin / growth-hormone secretagogue receptor (GHSR) within the broader GHRP family. The peptide sequence is sometimes reported with minor variants across the literature; the standard form supplied here is D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2. Pharmacology produces robust GH release, which is what underwrote the historical Japanese approval of Pralmorelin as a diagnostic agent for evaluating GH-secretory capacity. The trade-off relative to Ipamorelin (the GH-selective member of the family) is broader receptor coverage, GHRP-2 engages the cortisol and prolactin axes at higher doses, which is a real confounder for any cellular or in vivo readout that touches those secondary axes. For compounding pharmacy buyers, Vialdyne releases GHRP-2 as a lyophilised powder against a ≥99.0% main-peak HPLC specification. SPPS access to the hexapeptide is straightforward, so the standard release packet centres on peak-integration RP-HPLC plus ESI-MS identity. Catalogue strengths are 5 mg and 10 mg, sized to typical bench-scale and research-dispensing workflows. The selection rule between GHRP-2 and Ipamorelin is mechanism-based: clean GH selectivity points to Ipamorelin; maximum GH-release amplitude with tolerable secondary-axis effects points to GHRP-2.
Applications & buyer fit
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Sterile-filled vials are available with the full release packet (sterility, endotoxin, CCI); loose lyophilized powder ships with sequence verification.
Primary buyer fit: academic and contract research laboratories.
Specifications
Certificate of Analysis
Published released-batch COAs for GHRP-2, every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
VerifiedRequest full COA →GHRP-2
VD260428-G210080 · 99.11%
VerifiedRequest full COA →GHRP-2
VD260428-GR2081 · 99.64%
VerifiedRequest full COA →GHRP-2
VD260428-G25079 · 99.50%
Regulatory note
Sold as a pharmaceutical-grade active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Selected literature
Frequently asked questions
GHRP-2 is a short synthetic peptide, so the qualification set is compact: an RP-HPLC chromatogram with integrated main-peak area, ESI-MS confirming the expected mass, and sequence verification by peptide-mapping or amino-acid analysis. Add water content and counter-ion quantitation, since the residual counter-ion changes the net-peptide mass a pharmacy dispenses. If the material feeds a sterile-injectable preparation, extend the same released lot to LAL endotoxin per USP <85> and microbial limits per USP <61>/<62>. Every batch ships with a certificate carrying these results and a documented re-test date for procurement planning.
Reconstitute the lyophilised powder in bacteriostatic water for injection at a working concentration in the low milligram-per-millilitre range, then immediately sub-divide into the smallest single-use aliquots. As with the broader GH-axis class, freeze-thaw cycle count dominates measured-potency loss while slow temperature drift contributes far less, so the operational rule is to cap cumulative thaws at three or fewer per aliquot. Hold aliquots at -20 C. The sealed lyophilised vial itself follows a 24-month re-test window at -20 C, with the specific re-test date printed on the released-batch COA.
